A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with a dose response
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Dupuytren's contracture
- Focus Pharmacodynamics
- 30 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jun 2020.
- 30 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2019.
- 05 Mar 2016 Accrual to date is 0%, according to United Kingdom Clinical Research Network record.